- Telehealth Visits
- Insurance plan information
Laura Huppert, MD
She | Her | HersBreast Medical Oncology- Telehealth Visits
- Insurance plan information
Laura Huppert, MD
She | Her | HersBreast Medical Oncology- Telehealth Visits
- Insurance plan information
On this page
About me
Dr. Laura Huppert is an oncologist who cares for patients with all stages of breast cancer.
Huppert's research focuses on designing and conducting clinical trials to evaluate new cancer treatments, including ways to combine therapies so as to improve outcomes. She also studies metastatic breast cancer (that has spread to other body parts), including cancer that has reached the brain and leptomeninges (membranes surrounding the brain and spinal cord), and works to translate findings from the lab into care provided to patients.
Huppert earned her medical degree at Harvard Medical School. She completed a residency in internal medicine and a fellowship in hematology and oncology at UCSF. She is a member of the American Society of Clinical Oncology (ASCO) and has received an ASCO Merit Award as well as grants from the California Breast Cancer Research Program.
Education & training
Board certification
- Medical Oncology, American Board of Internal Med/Medical Oncology
Fellowship
- Hematology - Oncology, UCSF Graduate Medical Education
Residency
- Internal Medicine, UCSF Graduate Medical Education
Internship
- Internal Medicine, UCSF Graduate Medical Education
Degree
- MD, Harvard Medical School
My expertise
Specialties
Locations
My research
Clinical trials
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast CancerOpens in a new window
Recruiting
BORR is defined as the percentage of patients achieving complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors…Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialOpens in a new window
Recruiting
Progression-Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression as assessed by Response…Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive SubjectsOpens in a new window
Recruiting
IBCFS is defined as the time from the first dose of study medication until the date of ipsilateral invasive breast cancer recurrence, ipsilateral…A Study of XMT-1660 in Participants With Solid TumorsOpens in a new window
Recruiting
Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of XMT-1660
Publications
Showing 1-6 of 63 reviews
- February 25, 20265 out of 5 Stars
She is the best, and I am so fortunate to have her as my doctor.
- February 17, 20265 out of 5 Stars
Dr Huppert is really special! She is so smart and kind and compassionate
- February 14, 20265 out of 5 Stars
Absolutely amazing physician. Have never met a more outstanding doctor.
- February 6, 20265 out of 5 Stars
Dr. Huppert is absolutely amazing and I am super grateful for her!
- January 23, 20265 out of 5 Stars
We love Dr. Huppert!
- January 11, 20265 out of 5 Stars
Dr. Huppert is an excellent caregiver - emphasis on "care." She is open to questions and concerns, and has good advice and guidance.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.